Company intelligence
REJUVE HEALTH
Personalized, Preventative & Longevity Programs
About REJUVE HEALTH
A Nationwide Concierge Longevity Service Provider
Verified activity
Signals from REJUVE HEALTH
14 published signals
Research & Knowledge
REJUVE HEALTH published a 2026 Nature Communications research study measuring overnight clearance of amyloid-β and tau in humans.
Reported by Megan Retterath
Research & Knowledge
REJUVE HEALTH published findings from the PEARL trial, the first placebo-controlled RCT of rapamycin in 159 healthy adults, showing favorable aging biomarker trends and good tolerability at 5mg weekly over 48 weeks.
Reported by REJUVE HEALTH
Research & Knowledge
REJUVE HEALTH published findings from the NIA's Interventions Testing Program, which extended median lifespan 9-14% in mice at three fully independent sites starting at the equivalent of age 60.
Reported by REJUVE HEALTH
Research & Knowledge
REJUVE HEALTH published findings from the Dog Aging Project, which found significantly improved cardiac function in companion dogs with no adverse effects and received $7M in NIH funding to scale the trial to 580 dogs.
Reported by REJUVE HEALTH
Research & Knowledge
REJUVE HEALTH published findings from Marmoset studies conducted from 2024 to 2025, confirming slowed brain aging on MRI, preserved retinal function, and reduced cardiac hypertrophy across multiple organ systems.
Reported by REJUVE HEALTH
Research & Knowledge
REJUVE HEALTH received $7M in NIH funding to scale the Dog Aging Project trial to 580 companion dogs.
Reported by Megan Retterath
Research & Knowledge
REJUVE HEALTH published findings from the PEARL trial, the first placebo-controlled RCT of rapamycin in 159 healthy adults, showing favorable aging biomarker trends and good tolerability at 5mg weekly over 48 weeks.
Reported by Megan Retterath
Research & Knowledge
REJUVE HEALTH published findings from the NIA's Interventions Testing Program, which extended median lifespan 9-14% in mice at three fully independent sites starting at the equivalent of age 60.
Reported by Megan Retterath
Research & Knowledge
REJUVE HEALTH published findings from Marmoset studies conducted from 2024 to 2025, which confirmed slowed brain aging on MRI, preserved retinal function, and reduced cardiac hypertrophy across multiple organ systems.
Reported by Megan Retterath
Research & Knowledge
REJUVE HEALTH published the human TPE study conducted by the Conboy lab in Geroscience 2022/2024, confirming that therapeutic plasma exchange restores a younger systemic proteome.
Reported by REJUVE HEALTH
Research & Knowledge
REJUVE HEALTH published research showing that replacing half of aged mouse plasma with saline and albumin in the Conboy lab at UC Berkeley led to rejuvenation equivalent to infusing young blood.
Reported by REJUVE HEALTH
Research & Knowledge
REJUVE HEALTH published the human TPE study conducted by the Conboy lab at UC Berkeley in 2022/2024, confirming that therapeutic plasma exchange restores a younger systemic proteome and normalizes TLR4, JAK-STAT, MAPK, TGF-β, and NF-κB pathways.
Reported by Megan Retterath
Research & Knowledge
REJUVE HEALTH published a 2025 bibliometric analysis confirming 27% annual publication growth in MSC-EV clinical research since 2018.
Reported by REJUVE HEALTH
Research & Knowledge
REJUVE HEALTH published a 2025 bibliometric analysis confirming 27% annual publication growth in MSC-EV clinical research since 2018.
Reported by Megan Retterath